Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

This is a Phase 1 safety study of a new CAR-T cell therapy called LMY-920 for people with non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. CAR-T therapy involves modifying a patient's own immune cells to recognize and attack cancer. **You may be eligible if...** - You are over 18 with histologically confirmed non-Hodgkin lymphoma - Your lymphoma has relapsed or failed to respond to 2 or more prior lines of treatment - Your cancer does not involve the brain or spinal cord (no CNS lymphoma) - You have at least one measurable area of disease - Your organ function (liver, kidneys, blood counts) meets the study's safety requirements **You may NOT be eligible if...** - You have active CNS lymphoma - You have serious organ failure or infections - You have had certain recent treatments that would interfere with the study - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.